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ABSTRACT

TUMOR ASSOCIATED MACROPHAGES IN A MaFIA MOUSE MODEL

Adrianne B. Clifford
Department of Microbiology and Molecular Biology
Master of Microbiology

Recent evidence has shown the important role of macrophages in both tumor
development and progression. To investigate the role of macrophages we used a mouse
model known as MaFIA (Macrophage Fas Induced Apoptosis) mice that allows for the
selective deletion of macrophages. Mice were given melanoma cells at various stages of
depletion. Tumor mass was measured and organs were processed for flow cytometry to
measure melanoma cell migration.
The results show that mice receiving depletion treatment have larger tumor sizes
and weights than those mice retaining their macrophage population. We detect
metastasis in both the lung and kidney in both macrophage depleted and non depleted
mice. The more macrophages in an organ the larger the amount of melanoma positive
cells are detected.
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Background
Cancer has been defined as a group of diseases characterized by uncontrolled
growth and spread of abnormal cells (1). If the spread of these cells is not contained,
cancer can lead to death. Cancer can be caused by both internal and external factors.
External factors include tobacco, chemicals, infectious organisms, and radiation. Internal
factors include inherited mutations, mutations arising from metabolism, hormones, and
immune conditions (1).

These factors may act together or in sequence in the

development of cancer. Cancer is a major problem in the world today; it is the second
most common cause of death in the United States. In 2006 it is expected that 564,830
Americans will die of cancer, more than 1,500 people a day (1).
Current treatment for cancer depends on the type and stage of the cancer. Most
therapy involves surgical removal of the tumor in combination with one or more of the
following; radiation, chemotherapy, or hormones. The five year survival rate for all
cancers diagnosed in the years 1995-2001 is 65% (1). The five year survival rate does
not represent the proportion of people who are cancer free permanently, because cancer
can affect survival beyond the five year time point. The survival rate will also vary
among different types of cancers and the stage at diagnosis. Cancers diagnosed in early
stages have better survival rates.
Cancer development is a complex process that can take several years. The first
step in this process is the development of a transformed cell. A single cell must acquire
certain mutations that lead to the development of altered growth properties.

The

transformed cell can develop in many different tissues throughout the body. As the
transformed cell proliferates it forms a mass of tumor cells.
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Figure 1
Tumor development and progression.
From Kuby 2003.
In order for this mass to grow beyond a certain size it will need an increased amount of
nutrients. The blood stream is the source of nutrients so a new blood vessel must be
formed. A process known as angiogenesis generates new blood vessels in the stroma of
the tumor. With the delivery of nutrients from the blood stream the tumor can grow and
progress. In some cases the tumor cells become increasingly invasive as they grow,
breaking through the basal lamina of the tissue. Once the cells have invaded the lamina,
the tumor is now classified as malignant. The malignant cells can now spread through a
process called metastasis in which smaller masses of tumor cells break away from the
primary tumor and move through the blood or lymph to other sites of the body. These
masses can then establish other tumors called secondary sites.
When a patient is diagnosed with cancer they are classified into a stage of cancer
(1). The criteria for each stage of cancer are based on the primary tumor’s size along
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with the location in the body, and whether or not the cancer has spread. As the cancer
spreads it becomes increasingly harmful to the body and harder to treat. Treatment of
cancer has previously focused on the idea that cancer cells are rapidly dividing cells, but
this is not true for all cancer types. The search to cure cancer has been going on for
decades, but our treatments still remain crude and often ineffective. Significant amounts
of research have elucidated the genetic mutations acquired in the development of certain
cancers, but this has brought little change in our treatment strategies. Recent discoveries
have pointed to the immune system and its response to cancer.
It has been known for some time that the cell-mediated branch of the immune
system can recognize cancerous cells as foreign (2). In the early 1900s Paul Ehrlich
proposed the idea that cancer cells frequently arise within the body but are recognized as
foreign and eliminated, and that tumors develop only if they can escape detection by the
immune system (2). This concept is known as the Immune Surveillance Theory. This
theory gains support from several key observations. One observation is the increased
incidence of cancer in elderly patients; cancer is even known as a disease of the elderly
(1). The immune system in elderly patients is not as robust as in younger patients. This
weakened immune system leaves the elderly susceptible to cancer development, while in
younger patients their immune system keeps the cancer in check. As immune function
deteriorates the cancerous cells can evade the surveillance mechanisms and establish
tumors. Cancer incidence is increased in patients who have received a tissue transplant
and are taking immunosuppressive medications (2). Also the occurrence of certain types
of cancers in AIDS patients is significantly higher than in people with normal immune
systems, including cervical cancer, Kaposi sarcoma, and non-Hodgkin lymphoma (3).
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The Immune Surveillance Theory has not been proven but there is strong evidence to
support it. Some findings do contradict this theory, as cancer can occur in people of
younger ages in which their immune system should be fully functional. Nude mice,
which lack a thymus and therefore T cells, are not more susceptible to tumor induction
than other mice (2). The Immune Surveillance Theory remains unproved but it does
point researchers in the direction of the immune system involvement in cancer
development, specifically the cell-mediated branch of the immune system which includes
cytotoxic T cells, Natural Killer cells, and macrophages.
Cytotoxic T cells have been shown to have anti tumor effects. Cytotoxic T cells
have the ability to bind to and kill foreign cells. This binding is MHC class I restricted,
meaning that MHC class I is required for the binding of T cells to other cells in the body.
Cancer can evade death by cytotoxic T cells by decreasing the expression of MHC
molecules (2). Without the MHC the T cells cannot recognize and kill the cancer cell.
Natural Killer cells are not MHC restricted. Natural Killer cells are large granular
lymphocytes capable of cytotoxicity against altered self cells (2). These altered self cells
include tumor cells and virally infected cells. Natural Killer cells express CD 16, which
is a membrane receptor for the Fc region of IgG antibodies (2). Natural killer cells can
bind to these Fc regions and participate in antibody mediated cellular cytotoxicity
(ADCC), which destroys the cells to which the antibody is bound.
Macrophages also participate in ADCC and have the ability to phagocytose
foreign material including cancer cells (2).

In a typical bacterial infection the

macrophage is the second cell to respond to the pathogen. The presence of bacteria
activates the macrophage resulting in the secretion of pro-inflammatory cytokines to kick
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start the immune response. Macrophages engulf the bacteria. The ingested antigen is
degraded, processed and combined with MHC molecules to be presented on the surface
of the macrophage. The macrophage can present the antigen to other immune cells which
results in their activation. Once the bacteria have been cleared, macrophages have the
ability to shut down of the immune response and the repair process of damaged tissue.
These two processes are very different but each macrophage is capable of both processes.
Two different macrophage phenotypes have been proposed. These phenotypes do
not describe morphological differences but rather differences in the effector functions of
the macrophage, i.e. their cytokine profiles and phagocytic ability (4).

The M1

macrophage refers to the traditional macrophage: highly phagocytic with the secretion of
proinflammatory cytokines, IL-1, IL-6 and TNF-alpha. The M2 macrophage secretes
wound healing and anti-inflammatory factors such as TGF-B, IL-10.

This M2

macrophage serves to tone down the immune system and help repair any tissue damage
that occurred as a result of the response. In theory the M1 macrophage should be able to
phagocytose the cancer cells and process and present them to cytotoxic or helper T cells
to help start the cellular immune response, but in the case of cancer there is a breakdown
in this defense (4). The M1 phenotype is potentially harmful to the cancer while the M2
phenotype is infinitely helpful to the tumor. The ability of the tumor to convert the M1s
into M2s would ensure tumor growth and progression while remaining virtually
untouched by the immune system. The tumor can and does convert the M1 to an M2
through the development of a specialized microenvironment (4).
The microenvironment includes the cancer cells and the stroma that surrounds
the growing tumor. This stromal network is made up of the blood vasculature, immune
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cells, the extra cellular matrix and fibroblasts (5). Some scientists now believe that
tumors may arise from disruptions in tissue organization rather than an accumulation of
mutations (6). To understand tumors we must understand the environment in which they
grow and progress. The interactions between cancer cells and surrounding cells along
with extracellular components may be the determining factors in controlling or promoting
cancer growth (6).

These ideas suggest that the tumor is a product of the

microenvironment, but tumors have the ability to respond to the environment. Tumors
are known to produce many factors that can modulate this microenvironment.
Tumors are known to produce vascular endothelial growth factor (VEGF) and
macrophage colony stimulating factor (M-CSF), both of which have the ability to interact
with tyrosine kinase receptors and induce macrophage migration (4). The hypoxic center
of the tumor will release factors to attract a M1 type, but as the macrophage comes closer
it is exposed to the tumor microenvironment, and the M2 phenotype may be a result of
this exposure. Tumor cells secrete IL-10, IL-6, IL-4, MDF, TGF-B1, and PGF2, all of
which inhibit cytotoxic activity in macrophages (7). Macrophage expression of IL-2 is
greatly reduced in tumors because of exposure to IL-10 and PGf2 secreted by the tumor.
IL-2 stimulates both proliferation and activation of T cells and NK cells, the host’s
primary defense against cancerous cells. On the periphery of the tumor are vast amounts
of apoptotic bodies, which can act as immunosuppressants. Apoptotic bodies send a
message to macrophages that the ‘pathogen’ has been cleared, the response is over, and
now the cells are dying by apoptosis. These apoptotic bodies also trigger wound healing
and angiogenic responses from the macrophage in order to repair any tissue damage and
return to normal function.
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Macrophages have been shown to comprise a large amount of the immune cell
infiltrate in tumor masses. In certain cancers, such as breast cancer, macrophages can
comprise as much as 50% of the tumor mass (8). Such macrophages that enter the tumor
parenchyma are referred to tumor associated macrophages or TAMs. TAMS are also
thought to have an M2 phenotype. TAMs are thought to be involved in every aspect of
tumor development and progression (4). The first step is tumor invasion. The early tumor
consists of proliferating cancerous cells.

These cells grow and divide, eventually

breaking through the basement membrane, and this membrane is not easily compromised.
In order to break through, harsh proteolytic enzymes like matrix metalloproteinases
(MMPs) and cathepsin B must be upregulated (9). These enzymes are not ubiquitiously
expressed in all cell types but they are found in macrophages, and these macrophages can
be found in areas of basement membrane breakdown and invasion during early-stage
lesions in Polyoma virus middle T antigen (PyMT)-induced mammary tumors (9). It has
also been shown that coculturing tumor cells with macrophages increases the tumor cells
invasive properties using TNF-alpha and MMP (10). Figure 2 shows the roles of TAMs
in each stage cancer progression.
TAMs are known to play a role tumor growth. TAMs express a variety of factors
that stimulate tumor cell proliferation and survival. These factors include epidermal
growth factor (EGF), platelet-derived growth factor, TGF-B1, hepatocyte growth factor,
and basic fibroblast growth factor (bFGF) (11). The secretion of these factors solidifies
the theory that macrophages can stimulate tumor growth but TAMs may not behave the
same way in all tumor types.

A study using colony stimulating factor 1 (CSF-1)

knockout mice showed that both incidence and early growth of PyMT-induced benign

7

mammary tumors does not change, but growth of more advanced carcinoma stages is
disrupted (12). CSF-1 is an important cytokine in macrophage maturation, without it
macrophages cannot mature and function properly.
A tumor can only grow to a certain size without angiogenesis. Angiogenesis is
the process by which new blood vessels develop from the existing vasculature (8).
Angiogenesis is an essential event in tumor growth and spread and there is considerable
evidence that TAMs play a part in regulating angiogenesis. TAMs release a number of
pro-angiogenic cytokines and growth factors, including vascular endothelial growth
factor (VEGF), TNF-a, IL-8, and bFGF (8). TAMs also contain various angiogenesismodulating enzymes, such as MMP-2, MMP-9, MMP-7, MMP-12, and COX-2 (8). The
many pro-angiogenic functions of TAMs explain the correlations found between
increased TAM numbers and high vascular grades of many tumor types (13).
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Figure 2
The roles of different TAM subpopulations in tumor progression. 1. Invasion:
TAMs secrete proteolytic factors that enable the breakdown of the basement
membrane around areas of proliferating tumor cells. 2. Angiogenesis: TAMs
cooperate with tumor cells in order to secure blood supply to the tumor. TAMs upregulate a number of angiogenic factors and enzymes. 3. Immunosuppression:
TAMs secrete factors that inhibit antitumor functions of immune effector cells
within the tumor stroma. 4. Metastasis: a subpopulation of TAMs is associated with
the migration of tumor cells to the blood vessel and then aids in the establishment of
secondary sites. Figure adapted from Lewis et al 2006.
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Often newly formed blood vessels in tumors are disorganized and leaky (4).
Through these leaky vessels tumor cells can escape into the blood stream and then
establish secondary tumor sites in a process known as metastasis. TAMs are thought to
be involved in metastasis because tumor cells and TAMs have been found to migrate
together. TAMs are almost always associated with tumor cells that move away from the
main body of the tumor (14), and extravastion of tumor cells into blood vessels
frequently occurs at sites containing clusters of macrophages (15). The number of tumor
cells entering the bloodstream can be limited with the reduction of macrophage presence
along the vessels or inhibition of EGF signaling (8). This evidence suggests that TAMs
may play a major role in metastasis. It has even been proposed that macrophages fuse
with cancer cells, and that this fusion is essential to metastasis (16). Macrophages are
known to fuse with each other; this process takes place in the formation of osteoclasts or
giant cells (16). Macrophages are thought to fuse with tumor cells using a similar
mechanism.
Experiments utilizing both in vitro and in vivo work are pointing towards
macrophage involvement in cancer, but it is not definitive. To definitively test the role of
macrophages in tumor development and progression we need a system void of
macrophages. A macrophage knock-out mouse is impossible because the embryo does
not survive. Other methods of macrophage depletion such as chlodronate injections
remain crude and localized.
A system in which macrophages can be depleted on demand and this depletion is
both systemic and reversible would be ideal. This system does exist and it is known as
the MaFIA (Macrophage Fas Induced Apoptosis) mouse. The mice were developed by
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Dr. Sandra Burnett at the University of Kentucky. Fas is a membrane receptor found on
virtually all types of cells that has the ability to induce cell death by apoptosis. Figure 3
shows the mechanism of Fas induced apoptosis (2). Fas must trimerize in order to send
the apoptotic signal. The three Fas proteins come together on the cell membrane, and the
complex can then associate with the protein Fas associated death domain (FADD) see
figure 3a. This association results in the activation of procaspase 8 into caspase 8.
Activated caspase 8 starts the apoptotic caspase cascade which results in cell death (2).

Figure 3
from Kuby 2003
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In the MaFIA mouse the cells of the myeloid lineage undergo death by apoptosis
in the presence of the drug AP20187 (Ariad Pharmaceuticals).

The mechanism of

apoptosis utilizes the trimerization of Fas to activate the caspase 8 pathway, leading to
apoptosis of the cells. The MaFIA mice use a similar mechanism as that described by
Spencer et al (17). Spencer assembled a suicide gene, consisting of the cytoplasmic
domain of Fas linked to two units of the FK506 binding protein (FKBP). The suicide
gene also included a myristolation- targeting peptide, making the suicide gene specific
for T cells to accomplish their depletion in vivo (17). The MaFIA suicide gene is very
similar to that of Spencer’s.

It contains the Fas and FKBP but instead of the

myristolation-trageting peptide, human low affinity nerve growth factor receptor
(LNGFR) was included to allow membrane insertion (18). This suicide gene was placed
under the control of the cfms promoter allowing for expression only in cells of the
myeloid lineage (18). EGFP was also placed in the suicide gene to allow for easy
identification of transgene-expressing cells, because they would express GFP which is a
fluorescent protein. Figure 4 shows a schematic representation of the MaFIA transgene
(18).

Figure 4
from Burnett et al 2004.
The drug AP20187 from Ariad Pharmaceuticals causes trimerization and activation of the
Fas protein to cause apoptosis only in transgene-expressing cells see figure 5 (18).
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Expression of the Fas protein by
transgene-expressing cells.

Binding of the drug AP20187,
causes cell death by apoptosis.

Figure 5
Transgene expression on cell membrane and mechanism of
drug binding and induction of apoptosis.
This model allows us to test the role of macrophages by inducing a tumor into a
mouse void of macrophages.

Comparison of tumor growth in environments in the

presence of macrophages and in the absence of macrophages will yield powerful results.
We plan to use the MaFIA mouse model to deplete macrophages at various stages of
cancer development.

We hypothesize that tumors grown without macrophages will be

smaller, metastasize to a lesser degree and show a smaller amount of angiogenesis when
compared to the tumors grown with macrophages.
The experiment will have three groups of mice, each with a different depletion
regimen. Group one or ‘Tumor Control’ group will receive the tumor only, no depletion.
Group two or the ‘Before’ group will be depleted of macrophages and then the tumor will
be introduced. Group three, the ‘After’ group, in which the mice are given the tumor and
then the macrophages are depleted.

Both the ‘Before’ and ‘After’ groups will be

compared to the ‘Tumor Control’.
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Materials and Methods
Cell Culture
A mouse melanoma cell line, B16 F10 ATCC # CRL-6475, was grown in DMEM
medium supplemented with 10% bovine calf serum (Hyclone, Logan, Ut). Cells were
kept in a 37oC incubator supplied with 5% CO2. To prepare cells for injection the media
was changed 24 hours before trypsinizing. Cells were trypsinized using 1% Trypsin
(Gibco) dissolved in Hanks solution (Hyclone, Logan, Ut). A cell count was performed
using a hemocytometer and then cells were resuspend at a concentration of 5 x 106 cells
per ml. Subdermal injections consisted of 1 x 106 cells in 200 ul of medium. The mice
were anesthetized using Avertin, a toe pinch method was performed to ensure full
anesthetization and then the subdermal injection was performed using a 27 gauge needle
and a 1 cc syringe. The injection was placed on the back of the mouse in between the
shoulders.
Mice
The MaFIA mice were a gift from Dr. Sandra Burnett. All mice were housed in
the specific pathogen free (SPF) facility at BYU. Mice were used under the IACUC
protocol number 040806 with Dr. Kim O’Neill as the principal investigator. Breeding
pairs were established between two MaFIA positive mice. Not all mice were transgene
positive so pups were tested for transgene expression using a tail snip, the blood samples
from the tail were examined using a flow cytometer. Mice expressing the transgene will
also express GFP, while mice without the transgene will not. The tail was dipped in cold
ethanol and then cut with a scalpel. The tail was bled into a 96 well plate containing 150
ul of a 1:100 dilution of heparin in PBS.

Mice were divided into three different
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experimental groups. One group known as the Tumor control received the subdermal
injection of the melanoma cells only. The ‘before’ group received depletion treatment
and then the injection of melanoma cells. The ‘after’ group received the injection of the
melanoma cells and then underwent the depletion treatment. Both the ‘before’ and ‘after’
groups were compared to the tumor control group.
Depletion
Depletion of the positive mice was achieved using the drug AP20187 developed
by Ariad pharmaceuticals. Depletion was carried out as described previously (18). The
drug was dissolved in 100% ethanol at a concentration of 62.5 mg/ml. Injection volumes
were based on mice weight. Drug formulation includes Sterile PBS, 2% Tween in PBS
and PEG 400.

Mice were weighed each day before injections.

Injections were

administered through intra-peritoneal injections using a 27 gauge needle and a 1cc
syringe. Mice were given the five day depletion regimen as previously described (18).
After the five day period mice were given injections three times a week to maintain
depletion.
Tissue Collection and Staining
All animals were killed by C02 asphyxiation. A peritoneal lavage was taken for
each positive mouse. Lavage was performed by filling the peritoneal cavity with 5 ml of
clear HBSS, injected with a 27 gauge needle and a 5ml syringe. The cavity was then
rubbed with a wet needle cap to shake the macrophages free from the organs. The HBSS
was then retrieved from the cavity using a 21 gauge needle and a 5 ml syringe. The cells
were centrifuged at 1600 rpms for five minutes and then resuspended in 500 ul of clear
Hanks solution and analyzed using flow cytometry for the quantification of GFP positive
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cells.

Organs, specifically the lungs and kidney, and tumors of each mouse were

dissected out for analysis of melanoma cell migration. The organs were taken from the
mice, placed into a 24 well plate, and each well filled with 1.5 ml of clear HBSS. The
organs were then chopped up with scissors and transferred into a stomacher bag filled
with 1.5 ml of HBSS to be homogenized. Lungs were incubated with 15 ul of DNAse
collagenase solution at 370C for one hour. Once the organs were homogenized, the
sample was divided in half and filtered. The samples were centrifuged at 2000 rpm for 5
min and the supernatant was decanted. A red blood cell lysis was performed by adding 2
ml of Tris ammonium chloride lysis buffer and incubated for 2-5 min. After the 5 min 2
ml of HBSS was added and samples were again centrifuged and supernatant decanted.
An Fc block was added to samples containing macrophages and allowed to incubate for
10 min on ice, then the samples were washed twice with clear HBSS. 50ul of a 1:100
dilution of the melanoma antibody [ HMB45 + DT101 + BC199]ab732 (Abcam Inc,
Cambridge, MA) was added. This antibody is specific for melanoma cells and only binds
to melanoma cells. The antibody was allowed to incubate for one hour on ice in the dark.
The samples were then washed twice with HBSS and stained with a secondary antibody
Alexa 633 on ice for one hour. The samples were washed twice and then analyzed using
flow cytometry.
Flow Cytometry
Flow cytometric analysis was performed on a BD FACS Canto in the Protein
Core Facility. Data were collected and analyzed using Facs DIVA software. A cell sort
was also performed on the FACSvantage machine, the data was also analyzed using
FACS Diva. Cells were sorted into tubes containing 1 ml of bovine calf serum.
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Slide Preparation and Analysis
Samples from the cell sort and organ samples were placed onto slides using a
Cytospin. Cells were loaded into the cytospin and centrifuged at 800 for 3min. Slides
were then allowed to air dry. The slides were stained using May Grunwald stain, 4%
Geimsa and then rinsed briefly in distilled water. Some slides were not stained but
analyzed for fluorescence. The slides were once again allowed to air dry and then a cover
slip was placed on top of each slide with a drop of Cytoseal. Slides were analyzed using
a Zeiss Axioscop, a fluorescent microscope.
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Results
In order to initiate this experiment we needed to establish some key protocols
including our depletion and tumor induction methods. To confirm that our depletion was
working we conducted a depletion study in which three MaFIA positive mice were used.
One mouse designated as a control was left untreated, another mouse was mock treated,
and another was treated for depletion. The mice were injected for five consecutive days
as described above and then sacrificed twenty four hours from the last injection.
Peritoneal lavages were performed on all three mice and analyzed by flow cytometry (see
Figure 6). The treated mouse shows a level of GFP at 0.1% while the mock treated
mouse shows 61.1% and the positive untreated mouse shows 72.8%. These results
confirm that the method of depletion was working.
Once the depletion method was confirmed, protocols for the establishment of
tumors in the mice were investigated. Tumors were introduced into the mice using a
subdermal injection located on the back of the mouse in between the shoulders. The
injection consisted of 1 x 106 cells and was performed as previously described. A tumor
control study consisting of sixteen mice were divided into four groups, for sacrifice at 1,
2, 3, and 4 weeks after the injection of the tumor cells. About one week after the
injection there was a small visible lump on the back of the mouse. At week 2 a tumor
lump was clearly visible on the back of all mice.

At week 3 the mice appeared

encumbered due to the large tumor size and only one mouse out of four survived to the
four week time point. From our tumor control study we established that viability was
maintained until three weeks and then severely drops at four weeks. The means of the
tumor mass for each week are shown in figure 7. We chose to work with the two week
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time point because there was a considerable tumor mass and still maintain viability of the
mice. A large amount of variability was observed in the tumor sizes. This variability
could be due to many parameters, such as the cells, the uniformity of injections, and the
genetic variability of the mouse. In an effort to reduce the genetic variation we formed
new breeding pairs. Each pair is a brother and a sister who both tested positive with tail
snip analysis.

Figure 6.

Flow cytometry results from peritoneal lavages of depletion study
mice. Each histogram represents the amount of fluorescence in the
FITC channel. FITC and GFP are measured in the same channel.
These histograms quantify the number of GFP expressing cells, the
vast majority of these cells will be macrophages.
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Figure 7
Weights of Tumor Control Mice arranged by week.
Mouse #
1000
1002
1034
1007
1017
1023
1030
1031
1016
1024
1028
1021

Week
1
1
1
2
2
2
2
3
3
3
3
4

Tumor
Weight
0.0106
0.048
0.0861
0.042
0.035
0.162
0.041
2.4
0.577
10.42
4.53
17.93

Average
Weight

0.0482

0.1645

4.4817

Having established the depletion and tumor induction methods we can combine
these two methods to investigate the role of macrophages in tumor development and
progression. This experiment consisted of different treatment groups in order to compare
tumors grown in the presence of macrophages and in their absence. Group one was a
tumor control consisting of positive and negative mice which received just the subdermal
injection and were allowed to live for two weeks from the injection date. Group two was
termed the ‘before’ group consisting of positive mice that underwent the five day
depletion regimen.

On day five the mice received the subdermal injection of the

melanoma cells. Mice continued to receive depletion injections three times a week to
maintain depletion and then sacrificed two weeks from the date of subdermal injection.
Group three was the ‘after’ group consisting of positive mice who received the subdermal
injection and then three days later began the five day depletion regimen. Again the mice

20

received depletion injections three times a week to ensure depletion and were sacrificed
two weeks from the subdermal injection date.
After two weeks of tumor growth mice were sacrificed and a peritoneal lavage
was taken from each mouse to ensure depletion. The level of GFP fluorescence was
compared to that of a lavage from an untreated positive mouse.

The tumor was

measured by caliper and weighed to quantify mass. Our average tumor weight from the
tumor control group was 0.833g, from the ‘before’ group 0.896g, and from the ‘after’
group 0.9587g (see figure 8).

Figure 8 also shows the results from the caliper

measurements. The means of each group are highlighted in yellow.
Tumor
Control
Mice
424
NT
476
479
442
415
418
450
451
452
462
463
464
466
454
NT
410
412
408
459
461

Tumor
Weight
0.368
0.754
2.103
0.254
1.19
0.509
0.17
1.61
1.4
0.6
0.346
0.086
1.758
0.963
1.23
1.477
1.289
0.18
0.93
0.02
0.26
0.833

Caliper
Size
1.9
2.08
4.2
1.32
2.7
1.98
0.7
3.91
2.85
3.06
2.39
0.72
2.34
2.72
2.52
3.3
3.24
0.8
2.37
0.32
1.96
2.256

Before
Mice
428
441
471
472
473
443
447
448
469
470
449
434
437
439
NT
456
457

Tumor
Weight
0.66
0.3
0.599
1.74
1.846
0.89
0.763
0.816
1.114
1.876
0.18
0.715
0.264
1.27
0.485
1.14
0.58
0.896

Caliper
Size
2.23
1.14
1.92
4.65
3
2.55
1.17
2.94
3.3
7.1
0.8
4.14
2.03
3.45
2.6
2.24
2.1
2.785

After
Mice
421
426
427
453
455
429
432
433
458
460

Tumor
Weight
0.305
1.712
1.447
0.37
1.58
0.456
1.9917
0.915
0.42
0.39
0.958

Caliper
Size
1.98
4.32
4
1.54
2.6
1.08
3.42
2.66
1.95
1.3
2.485

Figure 8
Summary of all mice according to group. Tumor weights in grams
and Caliper sizes in mm2. Averages from each group highlighted in
yellow.
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2
Weight in Grams

1.8

Caliper measurement mm2

1.6
1.4
1.2
1
0.8
0.6
0.4
0.2
0
Tumor Control

Before

After

Figure 9
Tumor Sizes. A graphical representation of tumor weights in
grams and caliper measurements in mm2.
In figure 9 the ‘before’ and ‘after’ groups are slightly larger in comparison to the
tumor control group. When we compare the groups using a statistical test we do not
determine a statistically significant difference between the groups. The tumor control
group was compared to each of the treatment groups using a two sided t test. Comparing
tumor control and ‘before’ group showed no significant difference (p = 0.368), and tumor
control compared with ‘after’ also shows no significant difference (p = 0.309). The
weights of each tumor within treatment groups varied greatly. When caliper
measurements were compared no significant difference was found.
To analyze metastatic potential of tumors with and without macrophages
melanoma cell migration from the primary tumor site was measured. Organs from both
tumor control and depleted groups were dissected, processed, and stained for the presence
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of melanoma cells. The kidneys and lungs were dissected out from each mouse, this
particular cell line reports metastasis to the lungs and kidneys which is why these organs
were chosen. The organs were processed and stained as described above for analysis
using a flow cytometer.

The flow cytometer uses lasers to detect the green GFP

expressing macrophages. The measurement of GFP expressing cells correlates to our
depletion of macrophages; small amounts of GFP indicate depletion.

Figures 10-13 depict typical data graphs acquired from the flow cytometer. These
graphs came from the lung samples of the mice. Figure 10 shows lung data obtained
from mouse 478, a positive control.
depletion treatment.

This mouse did not receive the tumor or the

This mouse served as a positive control, to depict normal

macrophage populations in the lung of a healthy MaFIA positive mouse. There were
two distinct GFP populations, termed GFP high and GFP low because of their different
intensities of expression. Figure 11 shows data obtained from our depletion control
mouse 503. We can see that the GFP populations are greatly reduced in numbers when
compared to figure 10. A two sample t-test was used to compare the GFP populations of
the positive controls and the depletion controls this test showed statistical significance
between the low GFP populations (p= 0.0005) and the high GFP populations (p=0.0001).
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These controls were performed in order to obtain accurate comparisons when examining
mice in the before and after groups.

Figure 12 contains data from a mouse representative of the before group. The
high GFP population was decreased similar to the results seen in the depletion control,
but the low GFP population had slightly increased. These same results occurred in the
mice from the after group (see figure 13). A two-sample t-test was used and found that
mice in the before and after groups have significantly more (p= 0.041) cells in the GFP
low population than the depletion control.

No significance (p= 0.071) was found

between the GFP high populations. The GFP high population was depleted but the GFP
low population increased. This increase may be due to the presence of the tumor.
To detect the melanoma positive cells samples were stained with an antibody
specific for the melanoma cells.

The melanoma antibody is un- conjugated so a

secondary antibody conjugated with Alexa Flour 633 was used to detect the melanoma
cells. Cells bound by the Alexa antibody will be referred to as tumor positive cells.
Tumor cells were detected in both the kidneys and the lungs in all groups of mice. Flow
data were obtained in the form of graphs similar to the graph shown in figure 14. This
graph plotted GFP expression on the X-axis and the tumor positive expression on the Y-
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axis. Quadrant Q4 contains the GFP positive cells (the macrophages), quadrant Q1
contains the tumor positive cells (the melanoma cells) and quadrant Q2 contains cells that
are positive for both markers. Cells expressing both markers were termed double positive
cells. The majority of the double positive cells lie slightly higher on the scatter graph
than the normal macrophage cells. A small percentage of the double positive cells lie at
the very top of the scatter graph indicating a difference in size that may be due to
clumping or large fused cells.
Figure 14
Flow cytometry graph plotting
the GFP expression vs tumor
expression. These graphs
quantify the number of cells that
are GFP positive, tumor positive
and double positive.

Flow cytometry allowed for the quantification of the exact number of positive
cells for each stain. These numbers are expressed as percentages of the total sample of
30,000 cells. The percentages of GFP, Tumor, and double positive cells from control
mice are represented in figure 15. The positive control mice were left untreated, the
tumor control mice received only the tumor, and the depletion control mouse received
depletion injections alone. The numbers represent the amount of GFP positive cells and
melanoma positive cells from each tissue taken from the mouse, each tissue sample
measured 30,000 cells. The term PEC refers to the peritoneal exudates cells obtained
from the lavage. The table also quantifies the number of double positive cells from each
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tissue. These double positive cells were found to express both the GFP and the
melanoma marker.

Treatment

Mouse

478
none

Tumor

1234

8.27%
6.16%

NT

1.09%

1235
negative
mouse

4.31%

1233

470
Depletion
Only

Weight
gain

503

3.76%

10.10%
21.30%
Weight
loss

Tissue

GFP
(+)

Tumor
(+)

PEC
Lung
Kidney
PEC
Lung
Kidney
PEC
Lung
Kidney
PEC
Lung
Kidney
Tumor
PEC
Lung
Kidney
Tumor
PEC
Lung
Kidney
Tumor
PEC
Lung
Kidney

45.8
43.1
32.7
15.8
3.5
3.6
5.6
8
31.5
0.0
0.0
0.1
0.0
2.6
0.0
0.2
0.9
50.7
26.3
3.4
1.3
1.5
30.2

0.0
0.0
8.7
15.3
0.0
13.9
3.7
45
85.6
4.8
52.7
95.8
5.2
15.6
15.8
0.0
18.3

GFP
(+),
Tumor
(+)
0.0
0.0
0.7
1.8
0.0
1.2
0.0
0.9
0.4
0.1
1.9
0.2
11.8
26.8
5.2
0.0
2.2

Figure 15
Flow cytometry percentages from control mice
tissues measured for melanoma migration.
Each tissue sample measured 30,000 viable
cells.
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Treatment

Mouse
471

472

Before

473

469

1226

1227

1204
After
1205

499

Weight
Loss %
24.7

23.8

23.5

24.6

25.5

32.2

27.7

27.1

16.2

Tissue
PEC
Lung
Kidney
Tumor
PEC
Lung
Kidney
Tumor
PEC
Lung
Kidney
Tumor
PEC
Lung
Kidney
Tumor
PEC
Lung
Kidney
Tumor
PEC
Lung
Kidney
Tumor
PEC
Lung
Kidney
Tumor
PEC
Lung
Kidney
Tumor
PEC
Lung
Kidney
Tumor

GFP
(+)
15.1
6.7
2.6
3.4
8.8
20.4
3.1
0.2
1.2
11
3.7
4.2
4.7
18.8
1.6
1.1
0
0.2
0
0
0.5
0.2
0
1.2
1.2
0.1
0
8.4
1.3
4.2
0.2
15.4
10.7
26
-

Tumor
(+)
18
22.2
46.3
1.8
4.6
34.5
3.4
17.8
36.6
15.3
5.8
53.2
20.7
30.6
96.1
20.5
27.1
93.9
10
42.3
91.4
16.3
34.6
87.3
0
5
-

GFP (+),
Tumor (+)
10.6
4.4
10.4
2.3
5.8
17.7
1
18.1
19.2
1.8
10.5
13.7
1.6
1
0.1
0.6
2
0.1
0.7
1.9
0
1.6
1.9
0.8
0
5.5
-

Figure 16
Flow cytometry data from tissue samples. The numbers are
percentages of the tissue sample size 30,000 cells. These mice
were from treatment groups, of mice depleted before and after
tumor induction.
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Figure 16 contains the flow cytometry percentages for mice in the treatment
groups. This figure also contains a column for the percent weight change. This column
was important when considering the depletion process. It was previously reported that
mice undergoing the depletion regimen lost approximately 18.1 +/- 6.7% of their body
weight over the five day course (18). Each of our mice exhibited the expected weight
loss adding confidence to the depletion of these mice.

A peritoneal lavage was

performed for each mouse and GFP percentages can be found in figure 16.
Statistical analysis was performed to determine any significant differences between the
control groups and those in depletion groups.

The kidney samples exhibited large

amounts of background staining which varied greatly between mice and did not yield any
significant conclusions.

First a two sample t-test assuming equal variances was

performed to determine any significant difference in both tumor expression and GFP
expression in the lungs of tumor control mice compared with before mice and then after
mice. The original plan for the experiment was to compare results from the before and
after groups to the results from the tumor control group, any differences would be a result
from the depletion of macrophages. When the before group was compared to the tumor
control group for tumor expression no significant difference (p= 0.173) was found.
When the GFP expression of the before group was compared with the tumor control
group no significant difference was found (p= 0.306). The before group does not differ
significantly in tumor expression or GFP expression from the tumor control group. When
the after group was compared to the tumor control group for tumor expression a
significant difference was found (p= 0.004).

Then GFP expression was compared

between the after group and the tumor control group and a significant difference was
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found (p= 0.0004).

The after group had significantly higher tumor expression and

significantly lower GFP expression compared to the tumor control group. Once these
findings had been established the focus was turned to the double positive cells.

Treatment

Mouse
478

None
NT
1233
Tumor only
470
Depletion
only

503

Tissue
Lung
Kidney
Lung
Kidney
Lung
Kidney
Tumor
Lung
Kidney
Tumor
Lung
Kidney

Subpopulation
1
Tumor (+) of
GFP low cells

Subpopulation
1
Tumor (+) of
GFP high cells

Subpopulation
2
GFP (+) of
Tumor cells

0.2
59
0.0
17.9
47.2
49.9
72.9
24.1
59.7
36.1
0.0
24

1.1
0.0
90.5
100
0.7
-

2.2
84.8
0.0
34.7
13.6
78.8
2.4
42.7
88
6.6
0.0
92

Figure 17
Percentages of double positive expression in
subpopulations of cells from the control mice tissues.
Up until this point the double positive cells have been measured as a percentage
of total viable cells expressing both markers. The viable cell population was the parent
population and the double positive cells were a subpopulation of this parent. To get a
better picture of the amounts of cells expressing both markers the double positives were
expressed as a percentage of different parent populations. The new parent populations
were either the GFP positive population or the tumor positive population. When the GFP
expressing cells were selected as the parent population and then the tumor positive cells
within the GFP population were measured, this percentage was called subpopulation 1.
When the tumor positive cells were selected as the parent population then the GFP
positive cells within the tumor positive population were measured, this percentage was
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called subpopulation 2. Since the lung contained two GFP population High and Low
there were two different subpopulations for the lung samples. Figures 17 and 18 contain
the percentages of these different subpopulations.

Treatment

Mouse
471

472

Before

473

469

1226

1227

1204
After
1205

499

Tissue
PEC
Lung
Kidney
Tumor
PEC
Lung
Kidney
Tumor
PEC
Lung
Kidney
Tumor
PEC
Lung
Kidney
Tumor
PEC
Lung
Kidney
Tumor
PEC
Lung
Kidney
Tumor
PEC
Lung
Kidney
Tumor
PEC
Lung
Kidney
Tumor
PEC
Lung
Kidney
Tumor

Subpopulation
1
Tumor (+) of
GFP low cells
42.2
40.7
86.6
28.8
39.9
92.1
54.8
68.5
94.8
63.6
52.5
94.2
25.4
28.9
47.8
32.9
47.8
41.1
24
43.2
80.6
27.2
39.6
0.4
36.2
-

Subpopulation
1
Tumor (+) of
GFP high cells
97.9
100
100
100
95.6
97.2
90.8
95
10.2
-

Subpopulation
2
GFP (+) of
Tumor cells
26.2
42.3
9
34.3
84.2
15.1
16.9
81
16.6
24.4
88.9
9.3
15.1
69.9
2.3
21
86.4
1.3
18.4
28.8
14.8
34.3
84.1
30
77.6
-

Figure 18
Percentages of expression in subpopulations of cells
from treated mice tissues.
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Statistical analysis was again performed to determine any significant difference in
the double positive populations. Mice in the before group had significantly more double
positive cells in both lung (p= 0.043) and tumor (p= 0.019) samples than mice in the after
group. This means that the majority of macrophages remaining after depletion became
double positive cells. First a paired two sample t-test was performed to determine if the
tumor contained more double positive cells in either subpopulation than the lung. All
mice were used in this test and it was found that there were significantly (p= 0.0007 and
p= 0.002) more double positive cells contained in subpopulation 1 and 2 in the tumor
than in the lung. Two p-values exist for this test because of the two different methods
used to determine double positive cell subpopulations.
Mice that received the depletion injections and the tumor still contained GFP
expressing cells in the lavage, lung and kidney samples (see figure 12 and 13).

To

determine the identity of the remaining GFP expressing cells a cell sort was performed.
The cell sort allowed the separation of the GFP expressing cells from the rest of the cells
in kidney and tumor samples. The sort enabled the separation of the low GFP from the
high GFP cells in lung samples. The GFP expressing cells were separated using a cell
sorter and then placed onto a slide using a cytospin. The slides were then stained for
morphology to determine whether the cells were macrophages or neutrophils. It has been
previously determined that the low GFP cells are neutrophils and that the high GFP cells
are macrophages (18). The stains used included a May Grunwald stain, as well as a
Geimsa stain which stained the nuclei of the cells. Macrophages have a large circular
nucleus while the neutrophils contain a lobed nucleus and a pink cytoplasm. Lung
sample cells from the high GFP population were macrophages exhibiting a large central
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nucleus (see figure 18). The low GFP cells were identified as neutrophils, showing a
multi-lobed nucleus and characteristic pink cytoplasm.

The GFP population from the

kidney showed macrophage morphology (see Figure 18). Figure 18 also shows some
tumor positive cells; these cells were sorted out from the tumor sample as those
expressing the melanoma cell marker.

Figure 18
Photographs taken from slides stained for morphology.
GFP positive populations were isolated from both lung and
kidney samples. Figure also shows tumor positive cells.
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Cell sort results confirmed that the high GFP population in the lungs consisted of
macrophages and the low GFP cells were neutrophils. The fact that the kidneys still
maintained a macrophage population was unexpected. Depletion data for the kidneys has
yet to be fully described. How and why this population escaped depletion we do not
know, the presence of the tumor could have contributed to the depletion evasion.
The double positive cells were also stained for morphology in order to clarify
their characteristics. The double positive cells obtained from the cell sort were the
double positive cells measured from total viable cells as the parent population. The
double positive cells were thought to be a result of cell fusion. The macrophages may
have fused with the tumor cells, either through incomplete phagocytosis or a spontaneous
fusion. The possibility does exist that these double positives resulted from the antigen
presentation capabilities of the macrophages. The macrophages could have engulfed the
melanoma cells and processed and presented the melanoma antigen on their surface. Our
melanoma antibody could have bound to these antigen sites on the macrophage.
The literature has reported that macrophage cancer cell fusions occur and are
largely responsible for metastasis (19). When the tumor cell fuses with the macrophage it
obtains the migration and proteolytic abilities needed to break away from the primary
tumor to form secondary sites. By staining for morphology we could determine if these
cell fusions occurred in our model.
Pictures from the cell sort gave promising evidence of cell fusion both tumor cell
fusion, and tumor macrophage fusion (See Figure 19).
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Figure 19
Right, double positive cells isolated from tumor sample. Left, double
positive cells isolated from lung sample. Arrows indicate possible cell
fusions.
Upon dissection of the mice a considerable difference was noted between the
depleted and non depleted mice in the amount of blood vasculature surrounding and
within the tumor. After the lavage was performed and the organs taken from the mouse,
the body was turned over and the skin was peeled back revealing the primary tumor site.
The blood seen in and around these tumors is not a result from the dissection process;
these vessels are underneath the membrane layer of the skin. The following data are
photographs taken upon dissection of the mice. The following pictures may represent
angiogenesis but the blood may be due to hemorrhaging. Mice in the tumor control
group did not receive the depletion regimen and therefore remained healthy. Tumor
control mice were observed to display characteristics of healthy mice including, moving
freely about the cage, exhibiting normal grooming habits, and normal activity with each
other. The depleted mice did not display healthy mice behaviors. The depleted mice
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appeared lethargic, unresponsive, and appeared to have dandruff as a lack of grooming.
It is thought that the tumor on the back was irritating to the mice and they bumped and
scratched their backs along the bars of the cage. This induced bruising and hemorrhaging
around the site of the tumor. The non depleted mice would have energy to participate in
these activities while the depleted mice would be too weak, thus possibly creating the
difference seen. Figure 20 includes some of the photographs taken.

Figure 20
Photographs taken at the time of mouse dissection. The skin of each mouse was cut
and peeled back to reveal the site of the tumor. Figure shows top left, control
mouse which did not receive tumor or depletion. Top right shows a tumor control
mouse which relieved only the tumor. Bottom shows a depleted mouse which
received depletion treatment and the tumor.
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Discussion
With all the growth factors secreted by macrophages and TAMs we predicted that
the tumor size would be significantly smaller when compared with the tumor control, but
we did not obtain this result. No significance was found when the tumor control was
compared with macrophage depleted mice, but the depleted mice showed slightly larger
tumor weights. These results have been independently confirmed in a recent paper. This
paper used a colon cancer model and clodronate injections to deplete macrophages (20).
The rats underwent macrophage depletion and then rat colon cancer cells were introduced
into the rats. In their study the macrophage-depleted rats showed larger tumors and
decreased survival rates (20). The depleted rats were shown to have larger tumors, but
the tumors were less differentiated. The tumors from rats with macrophages showed
several features associated with malignant differentiation while the depleted tumors did
not (20).

These results showed the dual nature of macrophages in cancer.

When

macrophages were inhibited their cytotoxic functions were eliminated along with their
tumor maturation effects, resulting in larger tumors that failed to differentiate into
malignant tumors.
One explanation of larger tumors in depleted mice is the fact that both
macrophages and TAMs (both M1 and M2 phenotypes) were depleted. Therefore both
macrophages that would help the tumor and those that would hurt it were eliminated.
Another explanation lies in the type of tumor used in this model, a melanoma. The
location of melanoma the primary tumor was the skin, this location is important when
considering the immune environment of the skin. The skin is an anatomical barrier and is
in constant contact with foreign invaders. Macrophages located in the skin, known as
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Langerhans cells, would have the M1 phenotype as they are constantly stimulated by the
presence of antigen. A better cancer type for this experiment would have been a breast
cancer because macrophages located within the tissue of the breast would generally be
M2 macrophages. The breast is not an organ that has frequent contact with foreign
material; if an immune response did occur in the breast it would be wise to stop the
response quickly to eliminate tissue damage, and this is done by M2 macrophages.
It has been shown that large infiltrates of TAMs in tumors correlate with
prognosis and survival in different forms of cancer. A large infiltrate in cancers of the
breast correlates with a poor prognosis, while large infiltrates in melanoma, and cancers
of the stomach and colon correlate with a good prognosis (see Table 1 from Lewis et al
2006). The stomach and colon are also
environments in which the M1 phenotype
would dominate.

When we deplete

macrophages in a melanoma model we are
eliminating primarily M1 macrophages,
which would help in the defense against
the tumor. This depletion could explain
why depleted mice had slightly larger
tumors. It would be interesting to repeat
this experiment using a breast cancer model.
The object of this study was to obtain results from three different groups of mice,
the tumor control group, the before group and the after group. The results obtained from
the before group would be compared to the results obtained from the tumor control group
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to determine if macrophage depletion caused any significant changes. The after group
was also compared to the tumor control group. The melanoma migration analysis
revealed that mice in the after group had significantly more tumor positive cells (p=
0.004) and significantly lower GFP positive cells (p= 0.0004) when compared to the
tumor control. When the before group was compared to the tumor control group no
significance was found. Depletion of macrophages before the introduction of a tumor
does not significantly change the development and progression of the tumor. Depletion
of macrophages after the introduction of the tumor does change the development and
progression of the tumor. When macrophages are depleted after tumor induction a larger
amount of metastasis was seen to secondary sites, and a greater amount of depletion was
reached than depleting the macrophages before tumor induction.
Cells expressing both the GFP macrophage marker and the tumor marker were
found in the organ samples of the mice. These cells were referred to as double positive
cells and were the result of possible cell fusions. The double positive cells appear to have
a slightly different scatter pattern than those of just macrophages. The before group was
found to have significantly larger amounts of double positive cells in both the lung
(p=0.043) and tumor (p=0.019) than the after group. The before group did not achieve
the same level of depletion as the after group. The macrophages remaining in the before
mice became the double positive cells.
There were significantly (p= 0.0003) more double positive cells found in the
tumor samples than lung samples.

This result confirms the concept of a tumor

microenvironment. The microenvironment of the tumor encourages the fusion of the
macrophages to the cancer cells. The lung does not produce the same cytokines and
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factors that are found in the tumor, therefore the fusions do not occur at the same
frequency in the lungs.
The melanoma migration analysis revealed large percentages of double positive
cells in each organ sample and the morphology stains of the double positive cells showed
some evidence of cell fusions. These double positive cells may be cell fusions, meaning
that a macrophage has fused with the melanoma cell. Such fusions have been reported in
the recent literature (19). This fusion makes sense because in order for cancer cells to
have escaped the primary tumor site and migrated to a secondary location various tasks
must have been performed.

These tasks included, breaking through the basement

membrane, extravasation into the blood vessel, and establishment of a secondary site.
These events are not characteristic of a cancerous cell, but they are characteristic of a
macrophage. Fusion with a macrophage possibly provided the essential machinery for
metastasis from the skin on the back of the mouse into the lungs and kidneys. If these
double positives were responsible for metastasis then the more double positive found in
the tumor the more tumor positive cells should be found in the lung. To determine if the
amount of double positive cells in the tumor correlated with the amount of tumor positive
cells detected in the lung a regression analysis was performed. No correlation was found
(R squared = 0.385). This could be due to the variance that was found in the amount of
both double positives and tumor positives in each sample.
A recent paper described the process of fusion in macrophages, including a model
called ‘cellocytosis’ developed based on macrophage fusion in culture (16). Cellocytosis
begins when one macrophage binds to another and eventually engulfs it. The internalized
cell is encased in two plasma membranes which are then degraded and recycled and the
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cytoplasm and organelles are integrated into the accepting cell but nuclear integrity is
maintained (16). The resulting single cell is equal to two parent cells with two nuclei.
Once the macrophage has become multi-nucleated it has the ability to engulf large
extracellular components (16). This process is represented in Figure 21. This figure also
shows some photographs of macrophages in various stages of the fusion process.

Figure 21
Figure depicts the process of Cellocytosis: a hypothetical model. Step 1 one
macrophage binds to another and then in Step 2 the macrophage is internalized. In
Step 3 the two membranes fuse. Step 4 depicts the new cell that is the sum of the
two parent cells. Part c Internalized, membrane-bound, but not yet fused rat
alveolar macrophages in tissue culture. The bar represents 5 um. Figure adapted
from Vignery et al 2005.
Pictures of our samples obtained from the cell sort show cells in close contact
with partially defined membranes (see Figure 22). These cells could also have been in
the first stages of cell fusion as described in figure 21.
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Figure 22
Tumor positive cells taken at 100x.
These cells were isolated from the
tumor sample as cells expressing
only the melanoma marker.

The fusion findings from this and other studies suggest that macrophages have a
significant role in the development of the malignant phenotype of tumors. Without the
macrophages the tumor cannot metastasize and spread to the same degree as tumors with
macrophages. Another experiment using the rat colon cancer model; shows that tumors
grown in the presence of macrophages cannot achieve the same malignant phenotype as
those with macrophages (20).
These results show that macrophages play a part in the progression of cancer but
they are certainly not the sole contributors.

Even without macrophages the tumor

manages to establish a primary site, grow, and to an extent spread to secondary sites
within the organism. From this research it appears that macrophages are necessary to aid
in tumor migration however further work must be done to confirm these results. Future
research must be done to complete the cancer story, including chapters about
macrophages, fusions, metastasis, and other important cell types.
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